Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dedifferentiated liposarcoma and 1,25 dihydroxyvitamin D-induced paraneoplastic hypercalcaemia.

BMJ case reports·2026

Same author

Trapped Lung and Pneumothorax Ex Vacuo.

Clinical case reports·2026

Same author

A Case of Autoimmune Pulmonary Alveolar Proteinosis.

Clinical case reports·2026

Same author

A case of transformation of Waldenström's Macroglobulinemia to diffuse large B cell lymphoma.

Oxford medical case reports·2026

Same author

Carcinogenic NMDA Contamination of Drugs for Heartburn, Hypertension and Diabetes.

Cancer control : journal of the Moffitt Cancer Center·2021

Same author

Professional drivers at risk for venous thromboembolism.

Tropical doctor·2019

Search research articles

Related Experiment Video

Updated: Jun 23, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Recent Advances in CAR-T Therapy.

Meher Binte Ali¹

¹University of Maryland Medical Center, Baltimore, MD, USA.

Cancer Control : Journal of the Moffitt Cancer Center

|June 24, 2024

Summary

Chimeric antigen receptor (CAR) T-cell therapy offers a novel treatment for refractory hematological cancers by reprogramming a patient's immune cells. This review covers CAR-T manufacturing, side effects, and the emerging risk of secondary T-cell malignancies.

Keywords:

CAR-T therapy cytokine release syndrome lymphoma neurotoxicity

More Related Videos

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Experiment Videos

Last Updated: Jun 23, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Area of Science:

Immunotherapy
Oncology
Cellular Therapy

Background:

Chimeric antigen receptor (CAR) T-cell therapy represents a significant advancement in treating hematological malignancies resistant to conventional treatments.
This immunotherapy approach involves genetically modifying a patient's T cells to target and eliminate cancer cells.

Discussion:

Manufacturing processes for CAR-T cells are complex and critical for therapeutic efficacy.
Common adverse events associated with CAR-T therapy require careful management.
An emerging concern is the potential risk of developing secondary T-cell malignancies following treatment.

Key Insights:

CAR-T cell therapy is a potent immunotherapy for refractory hematological cancers.
Understanding the manufacturing process is key to successful CAR-T cell therapy.
Monitoring for and managing side effects, including secondary malignancies, is crucial.

Outlook:

Further research into optimizing CAR-T cell manufacturing and safety profiles is warranted.
Long-term surveillance for potential adverse events, such as T-cell malignancies, is essential.
Continued development aims to broaden the application and improve the safety of CAR-T cell therapies.